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Immunocytometry Systems (BDIS), San Jose, CA, USA) The current definition for remission of leukemia is the following a 30 min incubation at ambient temperature with presence of less than 5% blasts by morphologic examinthe monoclonal antibodies (mAb) of interest according to ation of the bone marrow.
2 Using this criterion, a remission the manufacturer's instructions. Cells were then fixed and marrow may still contain a substantial number of clonoanalyzed on a FACSort flow cytometer (BDIS). List mode genic neoplastic cells. Even with recent improvements in data were acquired and analyzed using CellQuest software cytopathologic techniques, reliable detection of less than (BDIS). Cell sorting was performed on mononuclear cells 1% neoplastic cells can be difficult. Recent reports indicate separated from bone marrow on a Ficoll-Hypaque density gradient and labeled with monoclonal antibodies at 4°C in phosphate-buffered saline (PBS) containing 0.2% sodium 
Chimerism analysis Case reports
Post-transplant levels of donor-and/or host-derived cells Patient 1 were monitored by PCR amplification of polymorphic regions of DNA termed short tandem repeat (STR) loci.
Patient 1 was a 6-year-old Caucasian female who was diagnosed with ALL in March of 1994, after presenting with a Briefly, unique STR alleles (termed informative) were determined by amplifying DNA isolated from the periph-1 month history of low-grade fever and bilateral leg pain. She was then treated with induction chemotherapy, foleral blood of the pre-BMT patient and the donor. Evaluation of a panel of nine STR loci permits differentiation lowed by consolidation therapy. A complete blood count (CBC) drawn approximately 1 year after the diagnosis between the donor and recipient genomic DNA in Ͼ95% of our studies. Amplified products were resolved on 6% revealed peripheral blasts. Relapse was confirmed by flow cytomeric analysis of a bone marrow aspirate, which sequencing gels and detected, due to the incorporation of fluorescent primers during amplification, using the Hitachi detected the CD10
Cytogenetics indicated a normal female karyotype FMBIO-100 Fluorescent Imager or the ABI 377 automated sequencer. One or two (if available) informative loci were of 46 XX in 20 out of 29 cells. The remainder of the cells were hyperdiploid with the majority having 47 or 50 chroselected for the post-BMT chimerism analysis of the patient. The percentage of donor and/or host DNA present mosomes. Following reinduction and consolidation therapy, allogeneic transplantation was considered. HLA typing of in the post-transplant sample was determined using the method described by Scharf et al 3 which compares the the family members revealed her 7-year-old sister to be a five out of six antigen match and the partially mismatched amplification intensity of a standard curve consisting of quantitated mixtures of pre-transplant DNA, with the related donor (PMRD) BMT was performed in May 1995. Conditioning therapy included total body radiation, VP-16, unknown post-transplant sample. Chimerism analysis of known mixtures indicate that our method is both accurate Ara-C, cytoxan and methylprednisolone. The patient received a graft that was partially depleted of T cells using (±0-5% error) and sensitive (2-5% threshold depending upon the STR loci amplified).
anti-CD3 (OKT3: Ortho) and rabbit complement. GVHD 
CD10
+ B lymphocytes enriched to 82% by cell sorting. Analysis reveals that the population is of donor origin without evidence of a persisting host population. 
CD34
+ phenotype consistent with the pre-BMT AML phenotype.
prophylaxis consisted of low dose cyclosporine and methylaspirate and biopsy revealed 4% atypical cells with morphology consistent with lymphoblasts. Flow cytometric prednisolone. The post-transplant course was relatively uncomplicated. Evidence of engraftment was noted before analysis revealed accelerated reconstitution of B lymphocytes with CD10 + B lymphocytes comprising 8% of the discharge on day +27. Due to high risk for relapse, patient 1 was enrolled on a protocol for pre-emptive donor leukocyte total WBC (Figure 1a ). In view of the possibility of early relapse, she received a third DLI at 5 × 10 5 /kg, and the dose infusion (DLI) therapy. Two doses of donor leukocytes were administered on day +60 and day +80, respectively. of cyclosporine was decreased. Bone marrow aspiration and biopsy, 1 month later, indicated disease remission. In Each infusion consisted of a total cell dose of 10 6 mononuclear cells/kg. Infusions were tolerated without compliaddition, flow cytometry analysis revealed Ͻ1.0% CD10 + B cell precursors (Figure 1b) . The patient subsequently cations and with no evidence of acute GVHD. Flow cytometric analysis demonstrated the typical pattern of immune received three DLI at 5 × 10 5 total nucleated cells/kg on day +240, day +260 and day +300. reconstitution, at day +30 and day +100. 
+ population purified to 90% using fluorescence-activated cell sorting and (b) total bone marrow nucleated cell population. Note that the total nucleated cell population is essentially 100% donor while the enriched population is of host origin. day +280 and day +349 revealed CD10+ B cell precursors demonstrated 6% blasts. The patient was then referred for evaluation for PMRD BMT. Examination of the bone marat 1.2% and 2.5%, respectively (Figure 1c and d) . From these results it was not possible to ascertain whether this row in January of 1996 revealed an AML expressing CD34, CD33 and CD7 without additional T cell markers. She CD10 + population represented recurrent disease or accelerated B cell reconstitution. Concurrent cytogenetics and began pre-BMT conditioning therapy for a PMRD BMT from her mother in February 1996. The patient received a morphologic evaluations from bone marrow aspirates indicated remission. To confirm remission status, CD19 + CD10 + graft that was partially depleted of T cells using anti-CD3 (OKT3) and rabbit complement. GVHD prophylaxis concells were enriched to 82% purity using fluorescent-activated cell sorting and evaluated for chimerism by PCR sisted of low dose cyclosporine and methylprednisolone. Engraftment was observed at day +16 and subsequent flow analysis of STR loci. Amplification of the CSF-R STR locus established the donor origin of the CD19 + CD10 + cytometry indicated typical immunophenotypic recovery. On day +54, immunophenotyping of a bone marrow aspirpopulation (Figure 2 ). The patient remains in good clinical condition, and to date has shown no evidence of relapse.
ate revealed a suspicious population expressing a CD33 + CD7 + CD34 + phenotype (Figure 3 ). Concurrent morphologic examination revealed Ͻ1% myeloblasts consistent Patient 2 with continued remission. Cytogenetic examination of the bone marrow revealed 9.5% host chimerism in interphase Patient 2 was a 15-year-old Caucasian female who was diagnosed with ALL in February 1994 after presenting with and 3.5% chimerism in metaphase. To confirm these results, CD7 + CD34 + cells were enriched to 90% purity fever, malaise, sore throat, and the presence of blasts in the peripheral blood. Immunophenotyping and morphologic using fluorescent-activated cell sorting and evaluated for chimerism by PCR analysis of STR loci. Amplification of examination of the bone marrow was consistent with T cell ALL with L1 morphology. Bone marrow aspirate analysis the VWF STR locus indicated that 100% of the sorted CD7 + CD34 + cells were of host origin and therefore indicafollowing induction and consolidation chemotherapy indicated remission status. Eighteen months from diagnosis, tive of relapsed leukemia (Figure 4) . A repeat bone marrow aspirate performed at day +61 revealed 9.0% myeloblasts 30% blasts in the bone marrow indicated disease relapse. A National Marrow Donor Panel (NMDP) search conducand an expansion of the blast population which was found to be CD45 dim CD33 + CD7 + CD34 + , consistent with AML. ted at this time revealed no HLA matched donors. Reinduction chemotherapy was then started, and a repeat bone marShe received a total of three doses DLI on days +63, +77 and +93, each at 5 × 10 5 /kg. The peripheral blast count and row aspiration and biopsy in November of 1995 total white blood cell count, however, continued to potential of combining MRD detection methods is evident from these two cases. We are conducting a more compreincrease. Despite the addition of chemotherapy and a phase I trial with compound 506 (Ara-G), she expired on 20 hensive study of MRD detection methods with the intent of initiating earlier treatment of recurrent disease. June 1996.
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